-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
Author: sunshine
On April 19, the CDE official website showed that Yuheng Pharmaceutical's recombinant fully human anti-LAG-3 monoclonal antibody injection was approved for clinical use in the treatment of advanced malignant tumors
LAG3 is an immune checkpoint that is the same inhibitory target as PD-1
In November 2017, Yuheng Pharmaceutical and WuXi Biologics reached a cooperation to jointly develop an anti-LAG3 fully human innovative antibody drug
At present, 9 drugs targeting LAG3 have entered the clinical stage in China
In addition, there are a number of LAG3/PD(L)1 dual antibodies in China that are conducting relevant clinical trials, namely IBI323 from Innovent, RO7247669 from Roche, MGD013 from Zai Lab/MacroGenics, EMB-02 from Anima Bio, and Merck & Co.